Katherine Liau

Katherine Liau

Pfizer Inc. - New York / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 4399375
-
person_outline Katherine Liau's MOST POPULAR ARTICLES
1-) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyEEW Cohen, LS Rosen, EE Vokes, MS Kies, AA Forastiere, FP Worden, ...Journal of Clinical Oncology 26 (29), 4708, 20087072008
2-) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyO Rixe, RM Bukowski, MD Michaelson, G Wilding, GR Hudes, O Bolte, ...The lancet oncology 8 (11), 975-984, 20075432007
3-) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II studyJP Spano, C Chodkiewicz, J Maurel, R Wong, H Wasan, C Barone, ...The Lancet 371 (9630), 2101-2108, 20082842008
4-) Efficacy and safety of axitinib in patients with advanced non–small-cell lung cancer: results from a phase II studyJH Schiller, T Larson, SHI Ou, S Limentani, A Sandler, E Vokes, S Kim, ...Journal of Clinical Oncology 27 (23), 3836-3841, 20092062009
5-) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trialNJ Robert, MN Saleh, D Paul, D Generali, L Gressot, MS Copur, ...Clinical breast cancer 11 (2), 82-92, 20111492011